Immatics Aktie

4,67 EUR +0,17 EUR +3,87 %

29.05.2025

STU

5,47 USD +0,33 USD +6,32 %

29.05.2025

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.554,22 Mio. EUR

KGV45,66Div. Rendite0,00%

WKNA2P72S

ISINNL0015285941

SymbolIMTX

Immatics Aktien News

Sortieren:Datum Meistgelesen

15.05.25finanzen.netImmatics: Bilanzvorlage zum letzten Quartal

13.05.25GlobeNewswireImmatics Announces First Quarter 2025 Financial Results and Business Update

23.04.25GlobeNewswireImmatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

WerbungImmatics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

30.03.25finanzen.netImmatics: Bilanzzahlen zum vergangenen Quartal

27.03.25GlobeNewswireImmatics Announces Full Year 2024 Financial Results and Business Update

15.01.25ZacksDown -16.85% in 4 Weeks, Here's Why Immatics (IMTX) Looks Ripe for a Turnaround

07.01.25ZacksImmatics (IMTX) Upgraded to Buy: What Does It Mean for the Stock?

19.11.24finanzen.netImmatics: Bilanzvorlage zum letzten Quartal

18.11.24ZacksWhat Makes Immatics (IMTX) a New Buy Stock

18.11.24ZacksImmatics (IMTX) Reports Q3 Loss, Tops Revenue Estimates

18.11.24GlobeNewswireImmatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME

08.11.24GlobeNewswireImmatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

05.11.24ZacksImmatics (IMTX) Expected to Beat Earnings Estimates: Should You Buy?

11.10.24GlobeNewswireImmatics Announces Pricing of $150 Million Public Offering

10.10.24BenzingaWhy Is Cancer-Focused Immatics Stock Trading Lower On Thursday?

10.10.24GlobeNewswireImmatics Announces Proposed $150 Million Public Offering

10.10.24GlobeNewswireImmatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

04.10.24GlobeNewswireImmatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

16.09.24GlobeNewswireImmatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update

06.09.24GlobeNewswireImmatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024

14.08.24finanzen.netImmatics verkündete Quartalsergebnis zum jüngsten Jahresviertel

13.08.24ZacksImmatics (IMTX) Reports Q2 Loss, Tops Revenue Estimates

13.08.24GlobeNewswireImmatics Announces Second Quarter 2024 Financial Results and Business Update

31.07.24GlobeNewswireImmatics Appoints Alise Reicin to Board of Directors

22.07.24ZacksWall Street Analysts Predict a 54.95% Upside in Immatics (IMTX): Here's What You Should Know

22.07.24ZacksHere's Why 'Trend' Investors Would Love Betting on Immatics (IMTX)

18.07.24GlobeNewswireImmatics Announces Upcoming Oral Presentation at ESMO Congress 2024

16.05.24finanzen.netImmatics: So viel setzte das Unternehmen zuletzt um

14.05.24GlobeNewswireImmatics Announces First Quarter 2024 Financial Results and Business Update

21.03.24GlobeNewswireImmatics Announces Full Year 2023 Financial Results and Corporate Update

18.01.24GlobeNewswireImmatics Announces Pricing of $175 Million Public Offering

17.01.24GlobeNewswireImmatics Announces Proposed Public Offering

16.01.24PR NewswireDISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

15.11.23finanzen.netImmatics hat Bilanz für das abgelaufene Quartal gezogen

14.11.23GlobeNewswireImmatics Announces Third Quarter 2023 Financial Results and Business Update

08.11.23GlobeNewswireImmatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

24.10.23GlobeNewswireImmatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy

12.09.23PR NewswireProtalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

11.09.23dpa-afxGNW-Adhoc: Moderna und Immatics geben strategische Multi-Plattform-Kollaboration zur Entwicklung innovativer Onkologie Therapeutika bekannt

Immatics News

Immatics News: auf dieser Seite finden Sie alle Immatics News und Nachrichten zur Immatics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Immatics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Immatics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.